{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:10:16Z","timestamp":1788801016451,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01554-3","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:17:36Z","timestamp":1788794256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel Strategies for the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Review"],"prefix":"10.1007","volume":"57","author":[{"given":"Tang","family":"Haowen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huo","family":"Yuhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cao","family":"Yinbiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Xiangfei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhanyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Shichun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"issue":"3","key":"1554_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10127","key":"1554_CR2","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M. Hepatocellular carcinoma [J]. Lancet. 2018;391(10127):1301\u201314.","journal-title":"Lancet"},{"issue":"25","key":"1554_CR3","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.1200\/JCO.2010.28.7805","volume":"28","author":"MB Thomas","year":"2010","unstructured":"Thomas MB, Jaffe D, Choti MM, et al. Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting [J]. J Clin Oncol. 2010;28(25):3994\u20134005.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1554_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma [J]. Nat Rev Dis Primers. 2021;7(1):6.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"1554_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update [J]. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"issue":"1","key":"1554_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","unstructured":"EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma [J]. J Hepatol. 2018;69(1):182\u2013236.","journal-title":"J Hepatol"},{"issue":"2","key":"1554_CR7","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases [J]. Hepatology. 2018;68(2):723\u201350.","journal-title":"Hepatology"},{"issue":"4","key":"1554_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000523997","volume":"11","author":"J Sun","year":"2022","unstructured":"Sun J, Guo R, Bi X, et al. Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition) [J]. Liver Cancer. 2022;11(4):315\u201328.","journal-title":"Liver Cancer"},{"issue":"3","key":"1554_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M, Kawamura Y, Hasegawa K, et al. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update [J]. Liver Cancer. 2021;10(3):181\u2013223.","journal-title":"Liver Cancer"},{"issue":"1","key":"1554_CR10","doi-asserted-by":"publisher","first-page":"100552","DOI":"10.1016\/j.aohep.2021.100552","volume":"27","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wu JL, Li LQ. Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus [J]. Ann Hepatol. 2022;27(1):100552.","journal-title":"Ann Hepatol"},{"issue":"1","key":"1554_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3349\/ymj.2021.62.1.29","volume":"62","author":"JY Lv","year":"2021","unstructured":"Lv JY, Zhang NN, Du YW, et al. Comparison of Liver Transplantation and Liver Resection for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus Type I and Type II [J]. Yonsei Med J. 2021;62(1):29\u201340.","journal-title":"Yonsei Med J"},{"issue":"40","key":"1554_CR12","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.3748\/wjg.v24.i40.4527","volume":"24","author":"SY Peng","year":"2018","unstructured":"Peng SY, Wang XA, Huang CY, et al. Better surgical treatment method for hepatocellular carcinoma with portal vein tumor thrombus [J]. World J Gastroenterol. 2018;24(40):4527\u201335.","journal-title":"World J Gastroenterol"},{"issue":"54","key":"1554_CR13","doi-asserted-by":"publisher","first-page":"93258","DOI":"10.18632\/oncotarget.18735","volume":"8","author":"JZ Ye","year":"2017","unstructured":"Ye JZ, Wang YY, Bai T, et al. Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update [J]. Oncotarget. 2017;8(54):93258\u201378.","journal-title":"Oncotarget"},{"issue":"32","key":"1554_CR14","doi-asserted-by":"publisher","first-page":"7289","DOI":"10.3748\/wjg.v22.i32.7289","volume":"22","author":"SL Chan","year":"2016","unstructured":"Chan SL, Chong CC, Chan AW, et al. Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016 [J]. World J Gastroenterol. 2016;22(32):7289\u2013300.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"1554_CR15","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/jcp.27324","volume":"234","author":"JC Wang","year":"2019","unstructured":"Wang JC, Xia AL, Xu Y, et al. Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis [J]. J Cell Physiol. 2019;234(2):1062\u201370.","journal-title":"J Cell Physiol"},{"key":"1554_CR16","doi-asserted-by":"publisher","first-page":"635731","DOI":"10.3389\/fonc.2021.635731","volume":"11","author":"F Luo","year":"2021","unstructured":"Luo F, Li M, Ding J, et al. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus [J]. Front Oncol. 2021;11:635731.","journal-title":"Front Oncol"},{"issue":"20","key":"1554_CR17","doi-asserted-by":"publisher","first-page":"33911","DOI":"10.18632\/oncotarget.15411","volume":"8","author":"JF Jiang","year":"2017","unstructured":"Jiang JF, Lao YC, Yuan BH, et al. Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges [J]. Oncotarget. 2017;8(20):33911\u201321.","journal-title":"Oncotarget"},{"issue":"5","key":"1554_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges [J]. Nat Rev Clin Oncol. 2018;15(5):325\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"1554_CR19","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","volume":"31","author":"RK Jain","year":"2013","unstructured":"Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers [J]. J Clin Oncol. 2013;31(17):2205\u201318.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1554_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/SLA.0b013e31824856f5","volume":"255","author":"AA Schnitzbauer","year":"2012","unstructured":"Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings [J]. Ann Surg. 2012;255(3):405\u201314.","journal-title":"Ann Surg"},{"issue":"3","key":"1554_CR21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/SLA.0000000000002942","volume":"271","author":"Z Wang","year":"2020","unstructured":"Wang Z, Peng Y, Hu J, et al. Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma: A Single Center Study of 45 Patients [J]. Ann Surg. 2020;271(3):534\u201341.","journal-title":"Ann Surg"},{"issue":"2","key":"1554_CR22","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1097\/JS9.0000000000002240","volume":"111","author":"S Loke","year":"2025","unstructured":"Loke S, Ong BDC, Ng J, et al. Safety and efficacy of minimally invasive associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): a systematic review and meta-analysis [J]. Int J Surg. 2025;111(2):2283\u201390.","journal-title":"Int J Surg"},{"issue":"2","key":"1554_CR23","first-page":"102","volume":"63","author":"S Peng","year":"2025","unstructured":"Peng S, Wang Y, Jin Y, et al. New perspectives on the diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus. Chin J Hepatobiliary Surg. 2025;63(2):102\u20136.","journal-title":"Chin J Hepatobiliary Surg"},{"issue":"2","key":"1554_CR24","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1148\/radiol.2017161975","volume":"284","author":"BY Zhong","year":"2017","unstructured":"Zhong BY, Ni CF, Chen L, et al. Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma [J]. Radiology. 2017;284(2):583\u201392.","journal-title":"Radiology"},{"issue":"9","key":"1554_CR25","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1097\/JS9.0000000000001691","volume":"110","author":"TY Zhou","year":"2024","unstructured":"Zhou TY, Tao GF, Zhou GH, et al. Comparison of drug-eluting bead with conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a randomized clinical trial [J]. Int J Surg. 2024;110(9):5527\u201337.","journal-title":"Int J Surg"},{"issue":"24","key":"1554_CR26","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/JCO.18.02184","volume":"37","author":"X Wei","year":"2019","unstructured":"Wei X, Jiang Y, Zhang X, et al. Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study [J]. J Clin Oncol. 2019;37(24):2141\u201351.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1554_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5582\/bst.2022.01019","volume":"16","author":"H Tang","year":"2022","unstructured":"Tang H, Cao Y, Jian Y, et al. Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review [J]. Biosci Trends. 2022;16(2):130\u201341.","journal-title":"Biosci Trends"},{"issue":"4","key":"1554_CR28","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in Advanced Hepatocellular Carcinoma [J]. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med"},{"issue":"1","key":"1554_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL CHENG","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J]. Lancet Oncol. 2009;10(1):25\u201334.","journal-title":"Lancet Oncol"},{"issue":"10126","key":"1554_CR30","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial [J]. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"20","key":"1554_CR31","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J]. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"4","key":"1554_CR32","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma [J]. J Hepatol. 2022;76(4):862\u201373.","journal-title":"J Hepatol"},{"issue":"8","key":"1554_CR33","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-alfa GK, Lau G, Kudo M, et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma [J]. NEJM Evid. 2022;1(8):EVIDoa2100070.","journal-title":"NEJM Evid"},{"issue":"7","key":"1554_CR34","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study [J]. Lancet Oncol. 2021;22(7):977\u201390.","journal-title":"Lancet Oncol"},{"issue":"10408","key":"1554_CR35","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study [J]. Lancet. 2023;402(10408):1133\u201346.","journal-title":"Lancet"},{"issue":"7","key":"1554_CR36","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial [J]. Lancet Oncol. 2018;19(7):940\u201352.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1554_CR37","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T YAU","year":"2020","unstructured":"Yau T, Kang YK, Kim TY, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial [J]. JAMA Oncol. 2020;6(11):e204564.","journal-title":"JAMA Oncol"},{"issue":"12","key":"1554_CR38","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial [J]. Lancet Oncol. 2023;24(12):1399\u2013410.","journal-title":"Lancet Oncol"},{"issue":"10474","key":"1554_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","volume":"405","author":"M Kudo","year":"2025","unstructured":"Kudo M, Ren Z, Guo Y, et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study [J]. Lancet. 2025;405(10474):203\u201315.","journal-title":"Lancet"},{"issue":"6","key":"1554_CR40","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1470-2045(25)00190-1","volume":"26","author":"J Zhou","year":"2025","unstructured":"Zhou J, Bai L, Luo J, et al. Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial [J]. Lancet Oncol. 2025;26(6):719\u201331.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1554_CR41","doi-asserted-by":"publisher","first-page":"505","DOI":"10.5582\/bst.2024.01394","volume":"18","author":"H Tang","year":"2025","unstructured":"Tang H, Zhang W, Cao J, et al. Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition) [J]. Biosci Trends. 2025;18(6):505\u201324.","journal-title":"Biosci Trends"},{"key":"1554_CR42","doi-asserted-by":"crossref","unstructured":"Cao Y, Tang H, Hu B, et al. Comparison of survival benefit between salvage surgery after conversion therapy versus surgery alone for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis [J]. Volume 25. HPB (Oxford; 2023. pp. 775\u201387. 7.","DOI":"10.1016\/j.hpb.2023.03.004"},{"key":"1554_CR43","doi-asserted-by":"crossref","unstructured":"Zhang W. Tong S, Hu B, Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial [J]. J Immunother Cancer, 2023, 11(9).","DOI":"10.1136\/jitc-2023-007366"},{"issue":"1","key":"1554_CR44","first-page":"9","volume":"30","author":"X Li","year":"2024","unstructured":"Li X, Li J, Zhang W, et al. Long-term outcomes of immunotherapy combined with targeted therapy followed by sequential radical surgery for initially unresectable hepatocellular carcinoma. Chin J Hepatobiliary Surg. 2024;30(1):9\u201314.","journal-title":"Chin J Hepatobiliary Surg"},{"issue":"1","key":"1554_CR45","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1186\/s12885-025-14543-9","volume":"25","author":"QY CHI","year":"2025","unstructured":"Chi QY, Liu QY, Wang SJ, et al. Lenvatinib combined with anti-PD-1 antibodies plus locoregional treatment for initial unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter real-world study [J]. BMC Cancer. 2025;25(1):1162.","journal-title":"BMC Cancer"},{"issue":"5","key":"1554_CR46","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","volume":"109","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, He W, Yang Z, et al. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study [J]. Int J Surg. 2023;109(5):1222\u201330.","journal-title":"Int J Surg"},{"issue":"1","key":"1554_CR47","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s12672-024-01026-9","volume":"15","author":"C Du","year":"2024","unstructured":"Du C, Wu H, Zhong T, et al. Interventional therapy combined with tyrosine kinase inhibitors with or without immune checkpoint inhibitors as initial treatment for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis [J]. Discov Oncol. 2024;15(1):164.","journal-title":"Discov Oncol"},{"issue":"2","key":"1554_CR48","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.acra.2024.08.058","volume":"32","author":"Y Lou","year":"2025","unstructured":"Lou Y, Zhang X. Hepatic Arterial Infusion Chemotherapy Enhances the Efficacy of Lenvatinib Plus PD-1 Inhibitors in Hepatocellular Carcinoma Patients with Tumor Thrombosis in the Inferior Vena Cava and\/or Right Atrium [J]. Acad Radiol. 2025;32(2):787\u201397.","journal-title":"Acad Radiol"},{"key":"1554_CR49","doi-asserted-by":"publisher","first-page":"1742116","DOI":"10.3389\/fimmu.2026.1742116","volume":"17","author":"S Wu","year":"2026","unstructured":"Wu S, Qiu F, Zhang F, et al. Hepatic arterial infusion chemotherapy combined with apatinib plus camrelizumab for advanced hepatocellular carcinoma with type Vp4 portal vein tumor thrombosis: a multicenter propensity score-matching analysis [J]. Front Immunol. 2026;17:1742116.","journal-title":"Front Immunol"},{"key":"1554_CR50","doi-asserted-by":"publisher","first-page":"1644027","DOI":"10.3389\/fimmu.2026.1644027","volume":"17","author":"J Jia","year":"2026","unstructured":"Jia J, Ning C, Wang Q, et al. Stereotactic body radiotherapy plus lenvatinib and sintilimab with and without transarterial embolization for advanced hepatocellular carcinoma with portal vein tumor thrombus: a dual-center, propensity score-matched retrospective analysis [J]. Front Immunol. 2026;17:1644027.","journal-title":"Front Immunol"},{"issue":"5","key":"1554_CR51","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1097\/JS9.0000000000000295","volume":"109","author":"J LU","year":"2023","unstructured":"Lu J, Guo JH, Ji JS, et al. Irradiation stent with 125 I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial [J]. Int J Surg. 2023;109(5):1188\u201398.","journal-title":"Int J Surg"},{"issue":"18","key":"1554_CR52","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1158\/1078-0432.CCR-23-0581","volume":"29","author":"YB Lee","year":"2023","unstructured":"Lee YB, Nam JY, Cho EJ, et al. A Phase I\/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma [J]. Clin Cancer Res. 2023;29(18):3650\u20138.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1554_CR53","doi-asserted-by":"publisher","first-page":"432","DOI":"10.5582\/bst.2025.01162","volume":"19","author":"Y CAO","year":"2025","unstructured":"Cao Y, Pan L, Ran Z, et al. Conversion therapy followed by surgery and adjuvant therapy improves survival in Barcelona C stage hepatocellular carcinoma - A propensity score-matched analysis [J]. Biosci Trends. 2025;19(4):432\u201344.","journal-title":"Biosci Trends"},{"issue":"2","key":"1554_CR54","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","volume":"72","author":"JM Llovet","year":"2020","unstructured":"Llovet JM. mRECIST for HCC: Performance and novel refinements [J]. J Hepatol. 2020;72(2):288\u2013306.","journal-title":"J Hepatol"},{"key":"1554_CR55","doi-asserted-by":"crossref","unstructured":"Gao S, Hu Y, Cao Y et al. Sequential Surgery Following Conversion Therapy Based on Combination of Immune Checkpoint Inhibitors and Antiangiogenic Targeted Drugs as a Potential Approach for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Prospective Study [J]. J Gastrointest Oncol, 2026","DOI":"10.21037\/jgo-2026-1-0147"},{"key":"1554_CR56","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ijsu.2017.06.082","volume":"44","author":"M Hamaoka","year":"2017","unstructured":"Hamaoka M, Kobayashi T, Kuroda S, et al. Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: A retrospective cohort study [J]. Int J Surg. 2017;44:223\u20138.","journal-title":"Int J Surg"},{"issue":"12","key":"1554_CR57","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1245\/s10434-007-9549-7","volume":"14","author":"WY Lau","year":"2007","unstructured":"Lau WY, Lai EC. Salvage surgery following downstaging of unresectable hepatocellular carcinoma\u2013a strategy to increase resectability [J]. Ann Surg Oncol. 2007;14(12):3301\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1554_CR58","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12957-022-02691-2","volume":"20","author":"Y Hidaka","year":"2022","unstructured":"Hidaka Y, Tomita M, Desaki R, et al. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report [J]. World J Surg Oncol. 2022;20(1):228.","journal-title":"World J Surg Oncol"},{"issue":"11","key":"1554_CR59","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s11605-009-0998-0","volume":"13","author":"D Ban","year":"2009","unstructured":"Ban D, Shimada K, Yamamoto Y, et al. Efficacy of a hepatectomy and a tumor thrombectomy for hepatocellular carcinoma with tumor thrombus extending to the main portal vein [J]. J Gastrointest Surg. 2009;13(11):1921\u20138.","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"1554_CR60","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s12893-023-02291-1","volume":"23","author":"T Jiao","year":"2023","unstructured":"Jiao T, Tang H, Zhang W, et al. Long-term survival and portal vein patency with novel PVTT surgery approach in advanced HCC patients with Vp3\/4 PVTT following combination therapy of TKIs and PD-1 inhibitors [J]. BMC Surg. 2023;23(1):384.","journal-title":"BMC Surg"},{"issue":"1","key":"1554_CR61","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1038\/s41467-024-47420-3","volume":"15","author":"Z Li","year":"2024","unstructured":"Li Z, Liu J, Zhang B, et al. Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial [J]. Nat Commun. 2024;15(1):3260.","journal-title":"Nat Commun"},{"issue":"7761","key":"1554_CR62","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","volume":"570","author":"S Cristiano","year":"2019","unstructured":"Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer [J]. Nature. 2019;570(7761):385\u20139.","journal-title":"Nature"},{"issue":"12","key":"1554_CR63","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu D, Schilling B, Liu D, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma [J]. Nat Med. 2019;25(12):1916\u201327.","journal-title":"Nat Med"},{"issue":"4","key":"1554_CR64","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N Mcgranahan","year":"2017","unstructured":"Mcgranahan N. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future [J]. Cell. 2017;168(4):613\u201328.","journal-title":"Cell"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01554-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01554-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01554-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:02:55Z","timestamp":1788800575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01554-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1554"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01554-3","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This manuscript is a review article and does not involve any original research with human participants or animals conducted by the authors.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflicts of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"213"}}